SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

SpringWorks Therapeutics (Nasdaq: SWTX) announced that CEO Saqib Islam will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 7:30 a.m. PT. Interested parties can access the live webcast through the company's Investors & Media section. A replay will also be available for a limited time post-event.

SpringWorks is focused on developing medicines for severe rare diseases and cancer, featuring a robust oncology pipeline and strategic partnerships to enhance patient solutions.

STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 a.m. PT.

To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at https://ir.springworkstx.com. A replay of the webcast will be available on SpringWorks’ website for a limited time following the conference.

About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for patients with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients with cancer. For more information, visit www.springworkstx.com and follow @SpringWorksTx on Twitter and LinkedIn.

Contacts:
Kim Diamond
Vice President, Communications and Investor Relations
Phone: 203-561-1646
Email: kdiamond@springworkstx.com

Samantha Hilson Sandler
Director, Investor Relations
Phone: 203-461-5501
Email: samantha.sandler@springworkstx.com  

FAQ

When will SpringWorks Therapeutics present at the J.P. Morgan Healthcare Conference?

SpringWorks Therapeutics will present at the J.P. Morgan Healthcare Conference on January 9, 2023, at 7:30 a.m. PT.

How can I watch the SpringWorks Therapeutics presentation?

You can watch the SpringWorks Therapeutics presentation live via their Investors & Media section on their website.

What is the focus of SpringWorks Therapeutics?

SpringWorks Therapeutics focuses on developing life-changing medicines for patients suffering from severe rare diseases and cancer.

What type of products does SpringWorks Therapeutics develop?

SpringWorks Therapeutics develops targeted oncology products for rare tumor types and genetically defined cancers.

Where can I find more information about SpringWorks Therapeutics?

More information about SpringWorks Therapeutics can be found on their website at www.springworkstx.com.